#METABOLOMICS WORKBENCH Masatomo_Takahashi_20230525_050334 DATATRACK_ID:4042 STUDY_ID:ST002729 ANALYSIS_ID:AN004425
VERSION                          	1
CREATED_ON                       	11-09-2023
#PROJECT
PR:PROJECT_TITLE                 	Role of AICARP, an endogenous AMPK activator, in improved endurance capacity in
PR:PROJECT_TITLE                 	diabetic mice during SGLT2 inhibition.
PR:PROJECT_TYPE                  	Wide targeted metabolomics & lipidomics
PR:PROJECT_SUMMARY               	Diabetes is often associated with increased risk of deleterious muscle mass and
PR:PROJECT_SUMMARY               	function or sarcopenia, thus leading to physical inactivity and metabolic
PR:PROJECT_SUMMARY               	disorders. Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an oral
PR:PROJECT_SUMMARY               	antidiabetic drug that promotes urinary excretion of glucose in the renal
PR:PROJECT_SUMMARY               	proximal tubules. However, how SGLT2 inhibition affects the skeletal muscle
PR:PROJECT_SUMMARY               	function in patients with diabetes remains elusive. Here, we examined the
PR:PROJECT_SUMMARY               	differential effect of CANA on the oxidative soleus and glycolytic EDL muscles
PR:PROJECT_SUMMARY               	from genetically obese diabetic db/db mice.
PR:INSTITUTE                     	Medical Institute of Bioregulation, Kyushu University
PR:DEPARTMENT                    	Metabolomics
PR:LABORATORY                    	Bamba lab.
PR:LAST_NAME                     	Takahashi
PR:FIRST_NAME                    	Masatomo
PR:ADDRESS                       	Maidashi 3-1-1, Higashi-ku, Fukuoka, Fukuoka, 8128582, Japan
PR:EMAIL                         	m-takahashi@bioreg.kyushu-u.ac.jp
PR:PHONE                         	0926426171
PR:PUBLICATIONS                  	https://onlinelibrary.wiley.com/doi/full/10.1002/jcsm.13350
PR:DOI                           	http://dx.doi.org/10.21228/M8VT66
#STUDY
ST:STUDY_TITLE                   	Improved Endurance Capacity of Diabetic Mice during SGLT2 Inhibition: Potential
ST:STUDY_TITLE                   	Role of AICARP, an Endogenous AMPK Activator.
ST:STUDY_SUMMARY                 	Diabetes is associated with an increased risk of deleterious changes in muscle
ST:STUDY_SUMMARY                 	mass and function or sarcopenia, leading to physical inactivity and worsening
ST:STUDY_SUMMARY                 	glycemic control. Given the negative energy balance during sodium-glucose
ST:STUDY_SUMMARY                 	cotransporter 2 (SGLT2) inhibition, whether SGLT2 inhibitors affect skeletal
ST:STUDY_SUMMARY                 	muscle mass and function is a matter of concern. However, how SGLT2 inhibition
ST:STUDY_SUMMARY                 	affects the skeletal muscle function in patients with diabetes remains
ST:STUDY_SUMMARY                 	insufficiently explored. We aimed to explore the effects of canagliflozin
ST:STUDY_SUMMARY                 	(CANA), an SGLT2 inhibitor, on skeletal muscles in genetically diabetic db/db
ST:STUDY_SUMMARY                 	mice.
ST:INSTITUTE                     	Medical Institute of Bioregulation, Kyushu University
ST:LAST_NAME                     	Takahashi
ST:FIRST_NAME                    	Masatomo
ST:ADDRESS                       	Maidashi 3-1-1, Higashi-ku, Fukuoka, Fukuoka, 8128582, Japan
ST:EMAIL                         	m-takahashi@bioreg.kyushu-u.ac.jp
ST:PHONE                         	0926426171
ST:SUBMIT_DATE                   	2023-05-25
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Mus musculus
SU:TAXONOMY_ID                   	10090
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Additional sample data
SUBJECT_SAMPLE_FACTORS           	-	13	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=13
SUBJECT_SAMPLE_FACTORS           	-	14	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=14
SUBJECT_SAMPLE_FACTORS           	-	15	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=15
SUBJECT_SAMPLE_FACTORS           	-	16	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=16
SUBJECT_SAMPLE_FACTORS           	-	61	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=61
SUBJECT_SAMPLE_FACTORS           	-	62	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=62
SUBJECT_SAMPLE_FACTORS           	-	63	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=63
SUBJECT_SAMPLE_FACTORS           	-	64	Animal:db/db | Treatment:Cana	RAW_FILE_NAME=64
SUBJECT_SAMPLE_FACTORS           	-	10	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=10
SUBJECT_SAMPLE_FACTORS           	-	11	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=11
SUBJECT_SAMPLE_FACTORS           	-	12	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=12
SUBJECT_SAMPLE_FACTORS           	-	57	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=57
SUBJECT_SAMPLE_FACTORS           	-	58	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=58
SUBJECT_SAMPLE_FACTORS           	-	59	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=59
SUBJECT_SAMPLE_FACTORS           	-	60	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=60
SUBJECT_SAMPLE_FACTORS           	-	9	Animal:db/db | Treatment:vehicle	RAW_FILE_NAME=9
SUBJECT_SAMPLE_FACTORS           	-	21	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=21
SUBJECT_SAMPLE_FACTORS           	-	22	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=22
SUBJECT_SAMPLE_FACTORS           	-	23	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=23
SUBJECT_SAMPLE_FACTORS           	-	24	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=24
SUBJECT_SAMPLE_FACTORS           	-	5	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=5
SUBJECT_SAMPLE_FACTORS           	-	6	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=6
SUBJECT_SAMPLE_FACTORS           	-	7	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=7
SUBJECT_SAMPLE_FACTORS           	-	8	Animal:db/+ | Treatment:Cana	RAW_FILE_NAME=8
SUBJECT_SAMPLE_FACTORS           	-	1	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=1
SUBJECT_SAMPLE_FACTORS           	-	17	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=17
SUBJECT_SAMPLE_FACTORS           	-	18	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=18
SUBJECT_SAMPLE_FACTORS           	-	19	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=19
SUBJECT_SAMPLE_FACTORS           	-	2	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=2
SUBJECT_SAMPLE_FACTORS           	-	20	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=20
SUBJECT_SAMPLE_FACTORS           	-	3	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=3
SUBJECT_SAMPLE_FACTORS           	-	4	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=4
SUBJECT_SAMPLE_FACTORS           	-	49	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=49
SUBJECT_SAMPLE_FACTORS           	-	50	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=50
SUBJECT_SAMPLE_FACTORS           	-	51	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=51
SUBJECT_SAMPLE_FACTORS           	-	52	Animal:db/+ | Treatment:vehicle	RAW_FILE_NAME=52
#COLLECTION
CO:COLLECTION_SUMMARY            	All mice were housed in a pathogen-free facility and maintained on a 12-h light
CO:COLLECTION_SUMMARY            	and 12-h dark cycle with free access to normal chow diet and water. CANA was
CO:COLLECTION_SUMMARY            	mixed at 0.03% (w/w) with CRF-1 and administered to 8-week-old db/+ and db/db
CO:COLLECTION_SUMMARY            	mice for 4 weeks. Food intake was calculated for 3 consecutive days each week
CO:COLLECTION_SUMMARY            	using the mouse feeder MF-4S. At the end of the experiments, 6 h-fasted mice
CO:COLLECTION_SUMMARY            	were anesthetized with isoflurane and blood samples were obtained from the
CO:COLLECTION_SUMMARY            	inferior vena cava. Skeletal muscles including soleus and extensor digitorum
CO:COLLECTION_SUMMARY            	longus were immediately frozen and stored at -80°C for metabolome and lipidome
CO:COLLECTION_SUMMARY            	analysis.
CO:SAMPLE_TYPE                   	Skeletal muscles
#TREATMENT
TR:TREATMENT_SUMMARY             	All mice were free access to normal chow diet and water. CANA was mixed at 0.03%
TR:TREATMENT_SUMMARY             	(w/w) with CRF-1 and administered to 8-week-old db/+ and db/db mice for 4 weeks.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Metabolites were extracted from frozen and crushed skeletal muscle (~10 mg) or
SP:SAMPLEPREP_SUMMARY            	serum (20 uL) with 1 mL of solvent mixture (methanol:chloroform:water = 10:4:4,
SP:SAMPLEPREP_SUMMARY            	v/v/v) containing piperazine-1,4-bis (2-ethanesulfonic acid) (PIPES) (0.63
SP:SAMPLEPREP_SUMMARY            	umol/L), 2-bromohypoxanthine (0.13 umol/L), free fatty acid (FA) 16:0 (13C16)
SP:SAMPLEPREP_SUMMARY            	(0.13 umol/L), diacylglycerol (DG) 15:0-18:1 (d7) (0.15 umol/L), and
SP:SAMPLEPREP_SUMMARY            	triacylglycerol (TG) 15:0-18:1 (d7) -15:0 (0.35 umol/L) as internal standards.
SP:SAMPLEPREP_SUMMARY            	The samples were vigorously mixed for 1 min and sonicated for 5 min. The
SP:SAMPLEPREP_SUMMARY            	extracts were then centrifuged at 16,000 × g for 5 min at 4°C, and the
SP:SAMPLEPREP_SUMMARY            	resultant supernatant was collected. Protein concentrations in the pellets were
SP:SAMPLEPREP_SUMMARY            	determined using a Pierce BCA Protein Assay Kit (Thermo Fisher Scientific,
SP:SAMPLEPREP_SUMMARY            	Massachusetts, USA). The collected supernatant (700 uL) was mixed with 235 uL of
SP:SAMPLEPREP_SUMMARY            	chloroform, and 155 uL of water, and then centrifuged at 16,000 × g for 5 min
SP:SAMPLEPREP_SUMMARY            	at 4°C. The aqueous (upper) layer (400 µL) was evaporated under vacuum, dried
SP:SAMPLEPREP_SUMMARY            	extracts were stored at −80°C until targeted polar metablome analysis. Prior
SP:SAMPLEPREP_SUMMARY            	to analysis, the dried aqueous layer was reconstituted in 50 uL of water. The
SP:SAMPLEPREP_SUMMARY            	organic (lower) layer (200 µL) was dried under a nitrogen stream, dried
SP:SAMPLEPREP_SUMMARY            	extracts were stored at −80°C until targeted lipidome analysis. Prior to
SP:SAMPLEPREP_SUMMARY            	analysis, the organic aqueous layer was reconstituted in 80 µL of
SP:SAMPLEPREP_SUMMARY            	methanol/chloroform (1/1, v/v)
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	Acyl-CoA and acyl-carnitine were analyzed via C18-LC/HRMS/MS.
CH:INSTRUMENT_NAME               	Shimadzu Nexera X2
CH:COLUMN_NAME                   	GL Sciences Inert Sustain C18 (150 × 2.1mm, 3um)
CH:COLUMN_TEMPERATURE            	40℃
CH:FLOW_GRADIENT                 	0-13.0 min, 2-95%B, 13.0-20.0 min, 95%B, 20.0-20.1 min, 95-2%B, 20.1-25.0 min,
CH:FLOW_GRADIENT                 	2%B
CH:FLOW_RATE                     	0.3 mL/min
CH:SOLVENT_A                     	5 mM ammonium acetate in H2O
CH:SOLVENT_B                     	ACN
CH:CHROMATOGRAPHY_TYPE           	Reversed phase
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	Thermo Q Exactive Orbitrap
MS:INSTRUMENT_TYPE               	Orbitrap
MS:MS_TYPE                       	ESI
MS:MS_COMMENTS                   	MS acquisition: FullMS (posi) Data processing/software: Reifycs Cascade ver. 1.0
MS:ION_MODE                      	POSITIVE
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS         	relative peak area
MS_METABOLITE_DATA_START
Samples	13	14	15	16	61	62	63	64	10	11	12	57	58	59	60	9	21	22	23	24	5	6	7	8	1	17	18	19	2	20	3	4	49	50	51	52
Factors	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:Cana	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/db | Treatment:vehicle	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:Cana	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	Animal:db/+ | Treatment:vehicle	
Acylcarnitine 10:0	0.3133	0.3413	0.2115	0.1949	0.0416	0.0513	0.0613	0.1430	0.4035	1.0664	0.4370	0.0348	0.0737	0.0734	0.0826	0.6264	0.1089	0.1750	0.2139	0.4586	0.4030	0.5862	0.5656	0.4000	0.4502	0.3726	0.2080	0.1492	0.5238	0.1684	0.4552	0.1187	0.0523	0.0603	0.0573	0.0606
Acylcarnitine 12:0	0.3904	0.4189	0.2502	0.2669	0.1216	0.1795	0.2342	0.3896	0.4461	1.0028	0.4177	0.1088	0.1555	0.1373	0.1985	0.6870	0.0882	0.1625	0.2204	0.4888	0.5112	0.6463	0.7044	0.5592	0.3848	0.2776	0.2482	0.1214	0.4406	0.1904	0.3171	0.0626	0.1439	0.1506	0.1029	0.1220
Acylcarnitine 14:0	0.2883	0.4305	0.2612	0.2441	0.2877	0.3459	0.4168	0.6199	0.2523	0.7277	0.2932	0.1768	0.2253	0.1756	0.4065	0.5367	0.0399	0.0877	0.2163	0.3970	0.4110	0.4714	0.5922	0.6025	0.2312	0.1157	0.1982	0.0698	0.2134	0.1196	0.1783	0.0283	0.2446	0.2568	0.1702	0.2095
Acylcarnitine 16:0	0.2794	0.5936	0.4019	0.2408	0.3860	0.4112	0.4357	0.6954	0.2572	0.6052	0.2007	0.1959	0.2949	0.2069	0.5091	0.3869	0.0255	0.0761	0.2636	0.6154	0.2873	0.2998	0.4859	0.4149	0.1589	0.1180	0.1900	0.0766	0.1547	0.1169	0.1022	0.0442	0.4116	0.4810	0.2326	0.3210
Acylcarnitine 18:0	0.0299	0.0499	0.0501	0.0257	0.0179	0.0201	0.0186	0.0330	0.0490	0.1017	0.0236	0.0157	0.0175	0.0145	0.0339	0.0770		0.0101	0.0335	0.0970	0.0603	0.0638	0.0764	0.0708	0.0326	0.0207	0.0289	0.0066	0.0303	0.0150	0.0111	0.0100	0.0262	0.0233	0.0110	0.0130
Acylcarnitine 18:1	0.0711	0.1584	0.1111	0.0558	0.1327	0.1245	0.1467	0.2329	0.0404	0.1522	0.0465	0.0734	0.0957	0.0788	0.1627	0.0822	0.0025	0.0164	0.0591	0.1423	0.0693	0.0816	0.1490	0.1002	0.0226	0.0272	0.0471	0.0176	0.0221	0.0257	0.0095	0.0024	0.0817	0.1097	0.0774	0.0993
Acylcarnitine 2:0	30.3820	46.0112	38.3293	26.9985	107.0460	139.0843	128.1574	177.3234	86.5248	70.9438	76.7160	107.0902	108.5033	109.1748	155.4571	69.0818	57.3843	47.6479	47.8406	53.7863	55.8839	62.2946	63.7992	48.9074	44.9798	50.0247	50.6809	47.7083	53.5789	43.0191	71.9437	48.6651	152.7138	165.6096	47.9553	75.2033
Acylcarnitine 4:0	1.2792	1.4089	1.1775	0.7942	1.2174	1.1398	2.0157	2.3469	1.7931	5.4662	2.9861	1.1439	2.2734	5.5583	2.9596	2.7585	0.9836	0.9598	1.3290	2.5312	1.5375	1.9028	2.3130	1.3719	2.2660	1.9398	0.9428	0.8701	2.3952	0.7121	3.0757	0.8347	1.7822	1.8170	0.6043	0.8833
Acylcarnitine 6:0	0.6760	0.5858	0.3475	0.4585	0.2541	0.3487	0.4295	0.6849	0.8415	2.8777	1.2357	0.1713	0.2636	0.3418	0.3690	1.7963	0.2154	0.3308	0.3672	0.9534	1.0455	1.5513	1.3774	0.8669	1.3061	0.7790	0.3836	0.2243	1.4138	0.2901	1.6678	0.3366	0.4514	0.5796	0.3074	0.3492
Acylcarnitine 8:0	0.2790	0.2751	0.1522	0.1602	0.0179	0.0230	0.0307	0.0533	0.3562	1.0604	0.4021	0.0175	0.0263	0.0330	0.0307	0.6104	0.0975	0.1604	0.1755	0.4061	0.3956	0.5859	0.5225	0.3265	0.5035	0.3623	0.1809	0.1277	0.5547	0.1487	0.5927	0.1117	0.0421	0.0447	0.0272	0.0292
Acylcoenzyme A 10:0	0.0240	0.0372	0.0297	0.0256					0.0933	0.1513	0.1150					0.1333	0.0371	0.0364	0.0540	0.0800	0.0795	0.0796	0.1005	0.0716	0.0828	0.0683	0.0533	0.0615	0.1101	0.0493	0.1076	0.0331				
Acylcoenzyme A 12:0	0.1545	0.2318	0.1362	0.1553					0.4279	0.5402	0.3727					0.4608	0.1430	0.1574	0.1910	0.3501	0.3146	0.3493	0.4458	0.3163	0.2502	0.2037	0.1737	0.1233	0.3152	0.1773	0.2521	0.1010				
Acylcoenzyme A 14:0	0.3265	0.6322	0.4895	0.3882					1.2250	1.7255	1.0698					1.6138	0.3565	0.5251	0.5973	1.1695	0.9993	1.1156	1.2560	1.2175	0.4523	0.5409	0.6120	0.3140	0.7176	0.4959	0.4997	0.1762				
Acylcoenzyme A 16:0	1.0684	1.8790	1.9163	2.1637	0.0260	0.0280	0.0256	0.0543	3.1953	2.9411	2.3475	0.0285	0.0357	0.0382	0.0529	2.6461	0.9079	1.6372	2.4919	2.7398	2.5670	2.3322	3.5101	3.2850	0.9093	0.8509	2.4099	1.3059	1.0505	1.7855	0.7119	0.2412	0.0527	0.0482	0.0146	0.0205
Acylcoenzyme A 18:0	0.1937	0.3904	0.4698	0.4927	0.0182	0.0218	0.0211	0.0278	0.5934	0.5157	0.4681	0.0253	0.0248	0.0309	0.0350	0.6393	0.1915	0.3200	0.5584	0.6822	0.5583	0.5922	0.9053	0.8541	0.4666	0.1614	0.7114	0.3189	0.4302	0.4568	0.3060	0.1776	0.0401	0.0433	0.0124	0.0179
Acylcoenzyme A 18:1	1.0967	1.6215	1.9863	1.8093	0.0292	0.0317	0.0313	0.0581	1.5391	2.4161	2.2198	0.0312	0.0433	0.0462	0.0586	1.9546	0.8368	1.5514	2.2165	2.2824	2.1796	2.3450	2.9026	2.2880	0.9270	0.7835	2.6851	1.5349	1.0177	1.6791	0.7815	0.3437	0.0622	0.0589	0.0151	0.0233
Acylcoenzyme A 2:0	0.0574	0.1178	0.0656	0.0725		0.0001			0.2287	0.1385	0.2004					0.2803	0.4073	0.1716	0.1406	0.2113	0.1262	0.1040	0.1392	0.1562	0.1993	0.2091	0.2246	0.1806	0.1092	0.1055	0.1917	0.3118	0.0029	0.0010	0.0002	0.0001
Acylcoenzyme A 3:0	0.0026	0.0032	0.0032	0.0055	0.0004	0.0003	0.0001		0.0104	0.0067	0.0097	0.0008	0.0007	0.0009	0.0005	0.0126	0.0108	0.0039	0.0059	0.0033	0.0126	0.0054	0.0095	0.0072	0.0157	0.0041	0.0075	0.0071	0.0105	0.0053	0.0130	0.0224	0.0006	0.0009		0.0005
Acylcoenzyme A 4:0	0.0080	0.0112	0.0086	0.0093					0.0258	0.0458	0.0413					0.0350	0.0131	0.0093	0.0157	0.0234	0.0267	0.0221	0.0368	0.0186	0.0341	0.0217	0.0159	0.0171	0.0342	0.0129	0.0473	0.0183				
Acylcoenzyme A 6:0	0.0147	0.0218	0.0165	0.0170					0.0369	0.0641	0.0542					0.0549	0.0136	0.0140	0.0201	0.0392	0.0381	0.0391	0.0418	0.0288	0.0450	0.0228	0.0170	0.0111	0.0500	0.0183	0.0598	0.0215				
Acylcoenzyme A 8:0	0.0170	0.0239	0.0191	0.0183					0.0445	0.0819	0.0677					0.0693	0.0176	0.0160	0.0325	0.0502	0.0418	0.0457	0.0525	0.0364	0.0633	0.0369	0.0319	0.0322	0.0749	0.0294	0.0788	0.0264
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	pubchem_id	inchi_key	kegg_id	other_id	other_id_type	ri	ri_type	moverz_quant	
Acylcarnitine 10:0									
Acylcarnitine 12:0									
Acylcarnitine 14:0									
Acylcarnitine 16:0									
Acylcarnitine 18:0									
Acylcarnitine 18:1									
Acylcarnitine 2:0									
Acylcarnitine 4:0									
Acylcarnitine 6:0									
Acylcarnitine 8:0									
Acylcoenzyme A 10:0									
Acylcoenzyme A 12:0									
Acylcoenzyme A 14:0									
Acylcoenzyme A 16:0									
Acylcoenzyme A 18:0									
Acylcoenzyme A 18:1									
Acylcoenzyme A 2:0									
Acylcoenzyme A 3:0									
Acylcoenzyme A 4:0									
Acylcoenzyme A 6:0									
Acylcoenzyme A 8:0									
METABOLITES_END
#END